Literature DB >> 12811508

Autoimmune reaction to type II collagen and cartilage degeneration in MRL/Mp- lpr/lpr mouse.

Maki Tanaka1, Katsuyuki Fujii, Michiko Tsuji, Takashi Sawai.   

Abstract

The early phase of cartilage degeneration was immunohistochemically examined in order to clarify the importance of autoimmune reaction against type II collagen in MRL/Mp- lpr/lpr (MRL/ l) mouse in an experimental model of rheumatoid arthritis (RA). Anti-type II collagen antibodies were detectable in 3-week-old mice and preceded the appearance of rheumatoid factors. Furthermore, mesenchymal cells and tartrate-resistant acid phosphatase-positive cells began to accumulate remarkably in the periphysis, a fibrochondro-osseous area in the bone marrow vicinity. The numbers of these cells increased with mice age, together with serum levels of anti-type II collagen antibodies. Immunostaining of the periphysis revealed expression of type II collagen, IgG, C3, Mac-3, MHC class II antigen Ia, and cathepsin-L. Osteoclast-like cells and macrophage infiltration into the lesion area were confirmed by transmission electron microscopy. The results indicate that cartilage degeneration in MRL/ l mouse may originate in the periphysis and progress via a pathway independent of synovial invasion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811508     DOI: 10.1007/s00296-003-0336-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  38 in total

1.  Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis.

Authors:  A Trabandt; W K Aicher; R E Gay; V P Sukhatme; M Nilson-Hamilton; R T Hamilton; J R McGhee; H G Fassbender; S Gay
Journal:  Matrix       Date:  1990-12

2.  Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B.

Authors:  Q Nguyen; J S Mort; P J Roughley
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

3.  Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1.

Authors:  G R Dodge; A R Poole
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  The synovium-cartilage junction of the normal human knee. Implications for joint destruction and repair.

Authors:  S A Allard; M T Bayliss; R N Maini
Journal:  Arthritis Rheum       Date:  1990-08

5.  Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen.

Authors:  P H Wooley; H S Luthra; C J Krco; J M Stuart; C S David
Journal:  Arthritis Rheum       Date:  1984-09

6.  Chemokine production by human chondrocytes.

Authors:  L Pulsatelli; P Dolzani; A Piacentini; T Silvestri; R Ruggeri; G Gualtieri; R Meliconi; A Facchini
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

7.  Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis.

Authors:  Y Iwata; J S Mort; H Tateishi; E R Lee
Journal:  Arthritis Rheum       Date:  1997-03

Review 8.  [Histopathological characteristics of rheumatoid arthritis--as a clue to elucidate its pathogenesis].

Authors:  M Kyogoku; T Sawai; K Murakami; J Ito
Journal:  Nihon Rinsho       Date:  1992-03

9.  Coexistence of renin and cathepsin B in secretory granules of granular duct cells in male mouse submandibular gland.

Authors:  K Sano; S Waguri; N Sato; E Kominami; Y Uchiyama
Journal:  J Histochem Cytochem       Date:  1993-03       Impact factor: 2.479

10.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.